

02/13/02
J.C. 812 U.S. PTO

02-15-02

PATENT

10/075213 PRO
02/13/02

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231
Sir:

Transmitted herewith for filing is the patent application
under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: FI5026 US PCT
INVENTORS: Begon, et al.
TITLE: PROCESS FOR PRODUCING FINE
MEDICINAL SUBSTANCES

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231,
on

February 13, 2002

Date of Deposit

Renee McElhinney

Signature

EL 916210871 US

Express Mail No.

APPLICATION ELEMENTS

1. <input checked="" type="checkbox"/>	*Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i>	Total Pages	<input type="text" value="13"/>
2. <input checked="" type="checkbox"/>	Specification <i>(preferred arrangement set forth below)</i> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	<input type="text" value="13"/>
3. <input checked="" type="checkbox"/>	Drawing(s) <i>(35 U.S.C. 113)</i>	Total Sheets	<input type="text" value="1"/>
4. Oath or Declaration		Total Pages	<input type="text" value="2"/>
a. <input checked="" type="checkbox"/>	Newly unexecuted (original or copy)		
b. <input type="checkbox"/>	Copy from a prior application <i>(37 CFR § 1.63(d))</i> <i>(for continuation/divisional with Box 16 completed)</i>		
i. <input type="checkbox"/>	<u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).		
5. <input type="checkbox"/>	Microfiche Computer Program <i>(Appendix)</i>		
6. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i>			
a. <input type="checkbox"/>	Computer Readable Copy		
b. <input type="checkbox"/>	Paper Copy <i>(identical to computer copy)</i>		
c. <input type="checkbox"/>	Statement verifying identity of above copies		

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part
of prior application no: PCT/GB00/03178, filed August 18, 2000.
Examiner _____, Group/Art Unit _____.
(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of Great Britain Application No. 9919693.3,
filed August 19, 1999. (The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (*cover sheet & document(s)*)

8. 37 CFR §3.73(b) Statement Power of
(when there is an assignee) Attorney

9. English Translation Document (*if applicable*)

10. Information Disclosure Copies of IDS
Statement (IDS)/PTO-1449 Citations

11. Preliminary Amendment

12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired


14. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

15. Other: Print EFS

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487
<i>(Insert Customer No. or Attach bar code label here)</i>


Ronald G. Ort, Reg. No. 26,969
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Mail Code: EMC-G1
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4656
Telefax (908) 231-2626

Aventis Docket No. FI5026 US PCT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Complete if Known

Application Number	Not Yet Assigned
Filing Date	February 13, 2002
First Named Inventor	Begon
Examiner Name	
Group / Art Unit	

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 740.00)

Attorney Docket No. FI5026 US PCT

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None

 Deposit Account

Deposit Account Number 18-1982

Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
161	740	201	370
166	330	206	165
167	510	207	255
108	740	208	370
114	160	214	80
SUBTOTAL (1)		(\$740.00)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims	Fee from below	Fee Paid
Total	18	-20**= 0	x 0	= 0
Independent Claims	1	- 3**= 0	x 0	= 0
Multiple Dependent			0	= 0

Large Entity	Small Entity	Fee Description
Fee Code	Fee (\$)	Fee Description
103	18	203 9 Claims in excess of 20
102	84	202 42 Independent claims in excess of 3
104	280	204 140 Multiple dependent claim, if not paid
109	84	209 42 **Reissue independent claims over original patent
110	18	210 9 **Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$0.00)

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
105	130	205 65 Surcharge - late filing fee or oath	
127	50	227 25 Surcharge - late provisional filing fee or cover sheet	
139	130	139 130 Non-English Specification	
147	2,520	147 2,520 For filing a request for reexamination	
112	920*	112 920* Requesting publication of SIR prior to Examiner action	
113	1,840*	113 1,840* Requesting publication of SIR after Examiner action	
115	110	215 55 Extension for reply within first month	
116	400	216 200 Extension for reply within second month	
117	920	217 460 Extension for reply within third month	
118	1,440	218 720 Extension for reply within fourth month	
128	1,960	228 980 Extension for reply within fifth month	
119	320	219 160 Notice of Appeal	
120	320	220 160 Filing a brief in support of an appeal	
121	280	221 140 Request for oral hearing	
138	1,510	138 1,510 Petition to institute a public use proceeding	
140	110	240 55 Petition to revive - unavoidable	
141	1,280	241 640 Petition to revive - unintentional	
142	1,280	242 640 Utility issue fee (or reissue)	
143	460	243 230 Design issue fee	
144	620	244 310 Plant issue fee	
122	130	122 130 Petitions to the Commissioner	
123	50	123 50 Petitions related to provisional applications	
126	180	126 180 Submission of Information Disclosure Stmt	
581	40	581 40 Recording each patent assignment per property (times number of properties)	
146	740	246 370 Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249 370 For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279 370 Request for Continued Examination (RCE)	
169	900	169 900 Request for expedited examination of a design application	
Other fee (specify)			
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$)	

Complete (If applicable)

Name (Print/Type)	Ronald G. Ort, Reg. No. 26,969	Registration No. (Attorney/Agent)	26,969	Telephone	(908) 231-4656
Signature	<i>Ronald G. Ort</i>			Date	February 13, 2002

WARNING:Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. Aventis Pharmaceuticals Inc. template